These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 5808572)

  • 1. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.
    Weiner W; Harrison W; Klawans H
    Life Sci; 1969 Sep; 8(17):971-6. PubMed ID: 5808572
    [No Abstract]   [Full Text] [Related]  

  • 2. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

  • 3. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.
    Godwin-Austen RB
    J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal homovanillic acid and parkinsonism.
    Miachon S; Dalmaz Y; Cottet-Emard JM; Peyrin L
    Biomedicine; 1974 Jul; 21(7):303-8. PubMed ID: 4433665
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
    Weiner WJ; Klawans HL
    J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 10. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
    Wilk S; Mones R
    J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebrospinal fluid homovanillic acid and iso-homovanillic acid: a gas-liquid chromatographic method.
    Dziedzic SW; Gitlow SE
    J Neurochem; 1974 Mar; 22(3):333-5. PubMed ID: 4829959
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of homovanillic acid in the cerebrospinal fluid of Parkinson's disease patients and control group].
    Voto Bernales J; Cruz GA; Davila E
    Rev Neuropsiquiatr; 1973 Mar; 36(1):46-52. PubMed ID: 4793023
    [No Abstract]   [Full Text] [Related]  

  • 13. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 16. A study of spinal fluid homovanillic acid (HVA) in patients with diseases of the nervous system.
    Mones RJ; Wilk S; Green J; Jutkowitz R
    Mt Sinai J Med; 1972; 39(5):478-85. PubMed ID: 4538762
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinsonism-dementia of Guam: treatment with L-dopa.
    Schnur JA; Chase TN; Brody JA
    Neurology; 1971 Dec; 21(12):1236-42. PubMed ID: 4257247
    [No Abstract]   [Full Text] [Related]  

  • 19. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 20. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.